For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Regulus Therapeutics Inc.

USPTO Granted Patents = 63

% Expired Patents = 38.1

CIPO Patents = 1

EPO Patents = 11

Forward Citations = 612

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

C Frank Bennett (27 out of 203 patents)

Balkrishen Bhat (27 out of 81 patents)

Susan M Freier (21 out of 261 patents)

4. Richard Holmes Griffey (21 out of 110 patents)

5. Eric G Marcusson (14 out of 31 patents)

6. Christine Esau (11 out of 14 patents)

7. B Nelson Chau (6 out of 6 patents)

8. Noga Yerushalmi (6 out of 10 patents)

9. Ravi Jain (6 out of 22 patents)

10. Ayelet Chajut (6 out of 8 patents)

11. Bridget Lollo (6 out of 6 patents)

12. Daniel J Hogan (4 out of 5 patents)

13. Jeremy Duffield (4 out of 6 patents)

14. Eric E Swayze (4 out of 206 patents)

15. Deidre A MacKenna (4 out of 7 patents)

Core Competencies:

MicroRNA

Polycystic Kidney Disease

Liver Cancer

Metabolic Disorders

Cellular Uptake

Oligomeric Compounds

Small Non-Coding RNAs

miR-122

miR-21

Fibrosis

Alport Syndrome

miR-155

63 patents: Sort by Forward Citations

1. 12559750 - Methods and Compositions for Treatment of Polycystic Kidney Disease (2026-02-24),

2. 12005120 - Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect (2024-06-11),

3. 11168325 - Methods for treatment of polycystic kidney disease (2021-11-09),

4. 10941400 - Compounds and methods for enhanced cellular uptake (2021-03-09),

5. 10633657 - Methods for treatment of polycystic kidney disease (2020-04-28),

6. 10584336 - Oligomeric compounds and compositions for use in modulation of small non-coding RNAs (2020-03-10),

7. 10301627 - Targeting microRNAs for the treatment of liver cancer (2019-05-28),

8. 10240151 - Compounds and methods for enhanced cellular uptake (2019-03-26),

9. 10150967 - MicroRNA compounds and methods for modulating miR-122 (2018-12-11),

10. 10138484 - Targeting microRNAs for metabolic disorders (2018-11-27),

11. 10093926 - Oligomeric compounds and compositions for use in modulation of small non-coding RNAs (2018-10-09),

12. 10072265 - Oligomeric compounds and compositions for use in modulation of small non-coding RNAs (2018-09-11),

13. 9994846 - MicroRNA compounds and methods for modulating miR-21 activity (2018-06-12),

14. 9994842 - Methods for use in modulating miR-122A (2018-06-12),

15. 9970011 - Methods for treatment of alport syndrome (2018-05-15),

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing innovative medicines targeting microRNAs to treat a range of diseases. The company utilizes its proprietary oligonucleotide technologies to modify the activity of microRNAs, which are key regulators of gene expression.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Regulus Therapeutics Inc.

63 Patents

#99 in San Diego, CA

#1,343 in California

#5,749 in US

#11,597 in the World

San Diego, CA, United States of America

Regulus Therapeutics Inc.

Forward Citations = 612

37 inventors:

C Frank Bennett (27 out of 203 patents)

Balkrishen Bhat (27 out of 81 patents)

Susan M Freier (21 out of 261 patents)

4. Richard Holmes Griffey (21 out of 110 patents)

5. Eric G Marcusson (14 out of 31 patents)

Please report any incorrect information to [email protected]

Loading…